Comparison of the efficacy and safety of tolterodine 2 mg and 4 mg combined with an α-blocker in men with lower urinary tract symptoms (LUTS) and overactive bladder: a randomized controlled trial-Reference-Cited by-同舟云学术

Comparison of the efficacy and safety of tolterodine 2 mg and 4 mg combined with an α-blocker in men with lower urinary tract symptoms (LUTS) and overactive bladder: a randomized controlled trial

Published:2015-09-23 Issue:2 Volume:117 Page:307-315
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Kim Tae Heon¹,Jung Wonho²,Suh Yoon Seok¹,Yook Soonhyun³,Sung Hyun Hwan¹,Lee Kyu-Sung¹³

Affiliation:

1. Department of Urology; Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Korea

2. Department of Urology; Dongsan Medical Center; Keimyung University School of Medicine; Daegu Korea

3. Department of Medical Device Management and Research; SAIHST; Sungkyunkwan University; Seoul Korea

Funder

Clinical Research Design Program

Samsung Medical Center

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.13267/fullpdf

Reference29 articles.

1. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder;Chapple;Eur Urol,2006

2. Benign prostatic hyperplasia: from bench to clinic;Yoo;Korean J Urol,2012

3. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction;Oelke;Eur Urol,2013

4. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society;Abrams;Neurourol Urodyn,2002

5. The prevalence of lower urinary tract symptoms in korean men aged 40 years or older: a population-based survey;Kim;Int Neurourol J,2014

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How Would You Manage This Patient With Benign Prostatic Hyperplasia?;Annals of Internal Medicine;2023-04

2. Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders;Pharmacological Reviews;2023-03-14

3. Treatment of benign prostatic hyperplasia: Update and future;Urological Science;2023

4. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I—Initial Work-up and Medical Management;Journal of Urology;2021-10

5. Considerations in Male Overactive Bladder;Contemporary Pharmacotherapy of Overactive Bladder;2018-09-26